Clinical Trials · NCT00764166
A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Enrollment
- 254
- Start date
- Jun 2003
- Locations
- 1 site, France
- Primary endpoint
- The primary endpoint was the PSA (biochemical) progression-free survival (PFS) of high-risk metastasis-free PC patients, treated with LH-RH agonist for one year with or without docetaxel after prior radical prostatectomy (RP) or radiotherapy (RT).